Addressing the Role of Glycated Albumin Non-Enzymatic Glycation in Retinal Vascular Diseases: GLY-230

Time: 2:15 pm
day: Day One


  • Compelling preclinical evidence of reversal of diabetic retinal vascular disease pathologies
  • Sharing a reversal in abnormal biomarkers (including VEGF) with a small molecule given orally and/or with multimodal administration possibilities
  • GLY-230 reverses in the documented direct pathogenic actions of glycated albumin (GA) and decreases in generation of AGEs which are also pathogenic in RVD